Showing results (111-120 of 147) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|June 29, 2016
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoEmiliano Cocco, Salvatore Lopez, Jonathan Black, et al.
Gynecologic Oncology|January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionDennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)Sangini S Sheth, Ji Eun Oh, Stefania Bellone, et al.
Gynecologic Oncology|July 15, 2017
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Gynecologic Oncology|May 31, 2022
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neuGhanshyam Yadav, Dana M Roque, Stefania Bellone, et al.
Gynecologic Oncology|August 23, 2019
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparibAnna Bianchi, Salvatore Lopez, Gary Altwerger, et al.
Clinical & Experimental Metastasis|June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
British Journal of Cancer|February 12, 2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerDana M Roque, Eric R Siegel, Natalia Buza, et al.
Gynecologic Oncology|November 28, 2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaJustin Harold, Stefania Bellone, Diego D Manavella, et al.
Gynecologic Oncology|January 12, 2019
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancersElena Bonazzoli, Emiliano Cocco, Salvatore Lopez, et al.
Pageof 15